دورية أكاديمية
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT
| العنوان: | Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT |
|---|---|
| المؤلفون: | Rovó, A, Gras, L, Piepenbroek, B, Kroeger, N, Reinhardt, HC, Radujkovic, A, Blaise, D, Kobbe, G, Niityvuopio, R, Platzbecker, U, Sockel, K, Hunault-Berger, M, Cornelissen, JJ, Forcade, E, Bourhis, JH, Chalandon, Y, Kinsella, F, Nguyen-Quoc, S, Maertens, J, Elmaagacli, A, Mordini, N, Hayden, P, Raj, K, Drozd-Sokolowska, J, de Wreede, LC, Mclornan, DP, Robin, M, Yakoub-Agha, I, Onida, F |
| المصدر: | Rovó , A , Gras , L , Piepenbroek , B , Kroeger , N , Reinhardt , HC , Radujkovic , A , Blaise , D , Kobbe , G , Niityvuopio , R , Platzbecker , U , Sockel , K , Hunault-Berger , M , Cornelissen , JJ , Forcade , E , Bourhis , JH , Chalandon , Y , Kinsella , F , Nguyen-Quoc , S , Maertens , J , Elmaagacli , A , Mordini , N , Hayden , P , Raj , K , Drozd-Sokolowska , J , de Wreede , .... |
| سنة النشر: | 2024 |
| الوصف: | Although CMML since long has been separated from MDS, many studies continue to evaluate the outcomes of both diseases after hematopoietic cell transplantation (allo-HCT) together. Data evaluating outcomes of a large CMML cohort after allo-HCT compared to MDS are limited. We aim to compare outcomes of CMML to MDS patients who underwent allo-HCT between 2010 and 2018. Patients ≥18 years with CMML and MDS undergoing allo-HCT reported to the EBMT registry were analyzed. Progression to AML before allo-HCT was an exclusion criterion. Overall survival (OS), progression/relapse-free survival (PFS), relapse incidence (including progression) (REL), and non-relapse mortality (NRM) were evaluated in univariable and multivariable (MVA) Cox proportional hazard models including interaction terms between disease and confounders. In total, 10832 patients who underwent allo-HCT were included in the study, there were a total of 1466 CMML, and 9366 MDS. The median age at time of allo-HCT in CMML (median 60.5, IQR 54.3–65.2 years) was significantly higher than in the MDS cohort (median 58.8, IQR 50.2–64.5 years; p < .001). A significantly higher percentage of CMML patients were male (69.4%) compared to MDS (61.2%; p < .001). There were no clinically meaningful differences in the distribution of Karnofsky score, Sorror HCT-CI score at allo-HCT, and donor type, between the CMML and MDS patients. RIC platforms were utilized in 63.9% of CMML allo-HCT, and in 61.4% of MDS patients (p = .08). In univariable analyses, we found that OS, PFS, and REL were significantly worse in CMML when compared with MDS (all p < .0001), whereas no significant difference was observed in NRM (p = .77). In multivariable analyses, the HR comparing MDS versus CMML for OS was 0.81 (95% CI, 0.74–0.88, p < .001), PFS 0.76 (95% CI 0.70–0.82, p < .001), relapse 0.66 (95% CI 0.59–0.74, p < .001), and NRM 0.87 (95% CI 0.78–0.98, p = .02), respectively. The association between baseline variables and outcome was found to be similar in MDS and CMML (all ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://pure.eur.nl/en/publications/28445213-bfbe-4f2b-a19f-8491fdb2556aTest |
| DOI: | 10.1002/ajh.27150 |
| الإتاحة: | https://doi.org/10.1002/ajh.27150Test https://pure.eur.nl/en/publications/28445213-bfbe-4f2b-a19f-8491fdb2556aTest https://pure.eur.nl/ws/files/122277334/American_J_Hematol_-_2023_-_Rov_-_Outcomes_of_CMML_patients_undergoing_allo_HCT_are_significantly_worse_compared_to_MDS_a.pdfTest http://www.scopus.com/inward/record.url?scp=85177890776&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D8E403C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ajh.27150 |
|---|